Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Q&A
  • About Us
    • Our Coverage
    • Team

SynAct Pharma

18.64 SEK

+1.97 %

Less than 1K followers

SYNACT

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.97 %
-5.38 %
-17.52 %
-17.52 %
-16.60 %
+17.97 %
-73.82 %
-65.52 %
+304.37 %

SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2012 and is headquartered in Lund, Sweden.

Read more
Market cap
1.05B SEK
Turnover
2.87M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27/5
2026

Interim report Q1'26

11/6
2026

General meeting '26

20/8
2026

Interim report Q2'26

All
Webcasts
Press releases
3rd party
ShowingAll content types
Regulatory press releaseyesterday

Change in number of shares and voting rights in Synact Pharma AB

SynAct Pharma
Regulatory press releaseyesterday

Förändring av antalet aktier och röster i SynAct Pharma AB

SynAct Pharma
Regulatory press release3/27/2026, 9:41 AM

Finansinspektionen: Flaggningsmeddelande i SynAct Pharma AB

SynAct Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release3/26/2026, 1:30 PM

SynAct Pharma doserar första patienterna i fas 2-studien RESOVIR-2 med resomelagon

SynAct Pharma
Press release3/26/2026, 1:30 PM

SynAct Pharma doses first patients in the Phase 2 RESOVIR-2 study with resomelagon

SynAct Pharma
Press release3/18/2026, 8:11 AM

BioStock: SynAct Pharma lays out dual strategy for resolution therapy at capital markets day

SynAct Pharma
Press release3/18/2026, 7:00 AM

SynAct Pharma presenterar på partnering- och investerarkonferensen BIO-Europe Spring® 2026 den 23–25 mars

SynAct Pharma
Press release3/18/2026, 7:00 AM

SynAct Pharma Presenting at Partnering and Investor Conference BIO-Europe Spring® 2026 on March 23-25

SynAct Pharma
Press release3/11/2026, 9:43 AM

Investor Studios: Kapitalmarknadsdag med SynAct Pharma sänds live 15.00

SynAct Pharma
Press release3/4/2026, 11:00 AM

Inbjudan till SynAct Pharmas kapitalmarknadsdag i Stockholm den 11 mars

SynAct Pharma
Press release3/4/2026, 11:00 AM

Invitation to SynAct Pharma’s Capital Markets Day in Stockholm March 11

SynAct Pharma
Third party research3/4/2026, 6:27 AM

Synact Pharma: Multiple shots on goal in 2026 for resomelagon - Edison

SynAct Pharma’s FY25 results reflect a year of solid execution, highlighted by the continued advancement of lead asset resomelagon in the Phase IIb ADVANCE trial in rheumatoid arthritis (RA). With enrolment completed in February 2026 (n=246), top-line...

SynAct Pharma
Press release3/3/2026, 3:25 PM

Redeye: SynAct Pharma: Interview about the directed share issue

SynAct Pharma
Press release3/3/2026, 3:23 PM

Redeye: SynAct Pharma: Cash Position Further Strengthened

SynAct Pharma
Press release3/3/2026, 7:43 AM

BioStock: SynAct Pharma secures 51,9 million SEK to strengthen clinical runway

SynAct Pharma
Regulatory press release3/2/2026, 10:20 PM

SynAct Pharma har genomfört en riktad nyemission av aktier om cirka 51,9 MSEK

SynAct Pharma
Regulatory press release3/2/2026, 10:20 PM

SynAct Pharma has carried out a directed issue of new shares of approximately 51.9 MSEK

SynAct Pharma
Regulatory press release3/2/2026, 4:37 PM

SynAct Pharma announces intention to carry out a directed issue of approximately 45 MSEK

SynAct Pharma
Regulatory press release3/2/2026, 4:37 PM

SynAct Pharma offentliggör avsikt att genomföra en riktad nyemission om cirka 45 MSEK

SynAct Pharma
Regulatory press release2/24/2026, 9:00 AM

SynAct Pharma utser Ann Kristin Led till CFO

SynAct Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.